Cargando…

Liposomal eribulin for advanced adenoid cystic carcinoma, gastric cancer, esophageal cancer, and small cell lung cancer

BACKGROUND: In this open‐label, Phase 1 study, we explore the safety and efficacy of E7389‐LF (liposomal formulation of eribulin) in Japanese patients with advanced solid tumors. METHODS: This open‐label, Phase 1 study enrolled Japanese adult patients to receive E7389‐LF for the treatment of advance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Udagawa, Hibiki, Takahashi, Shunji, Hirao, Motohiro, Tahara, Makoto, Iwasa, Satoru, Sato, Yasuyoshi, Hamakawa, Takuya, Shitara, Kohei, Horinouchi, Hidehito, Chin, Keisho, Masuda, Norikazu, Suzuki, Takuya, Okumura, Shiori, Takase, Takao, Nagai, Reiko, Yonemori, Kan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883537/ https://www.ncbi.nlm.nih.gov/pubmed/35864593 http://dx.doi.org/10.1002/cam4.4996

Ejemplares similares

Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort
por: Shitara, Kohei, et al.
Publicado: (2023)

Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors
por: Sato, Jun, et al.
Publicado: (2022)

Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin
por: Kawai, Akira, et al.
Publicado: (2017)

Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib
por: Ida, Hanae, et al.
Publicado: (2023)

Eribulin in Cancer Treatment
por: Swami, Umang, et al.
Publicado: (2015)

Eribulin mesylate in patients with refractory cancers: a Phase I study
por: Mukohara, Toru, et al.
Publicado: (2011)

Regression of brain metastases from breast cancer with eribulin: a case report
por: Matsuoka, Hiromichi, et al.
Publicado: (2013)

Short‐term and long‐term outcomes of laparoscopic colectomy with multivisceral resection for surgical T4b colon cancer: Comparison with open colectomy
por: Miyo, Masaaki, et al.
Publicado: (2020)

Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy
por: Shimomura, Akihiko, et al.
Publicado: (2019)

A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer
por: Sakiyama, T, et al.
Publicado: (2015)

Role of multimodality therapy in cIIIA-N2 non–small cell lung cancer: perspective(§)
por: Horinouchi, Hidehito
Publicado: (2016)

Eribulin mesylate in the treatment of metastatic breast cancer
por: Jain, Sarika, et al.
Publicado: (2012)

To combine or not to combine: anti-vascular endothelial growth factor therapies in EGFR mutation positive non-small cell lung cancer
por: Horinouchi, Hidehito
Publicado: (2020)

Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer
por: Iwasa, Tsutomu, et al.
Publicado: (2019)

Eribulin for Advanced Breast Cancer: A Drug Evaluation
por: Shablak, Alaaeldin
Publicado: (2013)

Case Studies in the Management of Metastatic Breast Cancer with Eribulin
por: Wilks, Sharon, et al.
Publicado: (2015)

In vitro radiosensitization by eribulin in human cancer cell lines
por: Benlloch, Raquel, et al.
Publicado: (2022)

Treatment response to eribulin and anlotinib in lung metastases from rare perianal adenoid cystic carcinoma: a case report
por: Zheng, Shengnan, et al.
Publicado: (2021)

Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study
por: Hattori, Masaya, et al.
Publicado: (2017)

A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer
por: Liu, B., et al.
Publicado: (2023)

Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study
por: Iizumi, Sakura, et al.
Publicado: (2017)

Correction to: Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study
por: Hattori, Masaya, et al.
Publicado: (2017)

Nivolumab‐induced radiation recall pneumonitis in non‐small‐cell lung cancer patients with thoracic radiation therapy
por: Noda‐Narita, Shoko, et al.
Publicado: (2022)

Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial—a multicenter retrospective study of eribulin in real life
por: Garrone, Ornella, et al.
Publicado: (2016)

Stathmin dynamics modulate the activity of eribulin in breast cancer cells
por: Yoshie, Mikihiro, et al.
Publicado: (2021)

Differences in the efficacy and safety of eribulin in patients with soft tissue sarcoma by histological subtype and treatment line
por: Nakano, Kenji, et al.
Publicado: (2021)

Eribulin-induced liver dysfunction as a prognostic indicator of survival of metastatic breast cancer patients: a retrospective study
por: Kobayashi, Takayuki, et al.
Publicado: (2016)

Eribulin in the Management of Advanced Breast Cancer: Implications of Current Research Findings
por: Kok, Victor C.
Publicado: (2015)

Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy
por: Doherty, Mark K, et al.
Publicado: (2015)

Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function
por: Tan, Antoinette R., et al.
Publicado: (2015)

Inhibitory effects of iron depletion plus eribulin on the breast cancer microenvironment
por: Goto, Wataru, et al.
Publicado: (2020)

Eribulin drug review
por: Shetty, Nishitha, et al.
Publicado: (2014)

Eribulin mesylate exerts antitumor effects via CD103
por: Oya, Kazumasa, et al.
Publicado: (2023)

Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY)
por: Ohtani, Shoichiro, et al.
Publicado: (2018)

Study on the progression types of cancer in patients with breast cancer undergoing eribulin chemotherapy and tumor microenvironment
por: Kashiwagi, Shinichiro, et al.
Publicado: (2018)

Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer
por: Muñoz-Couselo, Eva, et al.
Publicado: (2011)

Oncology Nursing Support for Safe and Effective Use of Eribulin in Metastatic Breast Cancer
por: Donovan, Diana, et al.
Publicado: (2014)

Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice Guide
por: Ro, Jungsil, et al.
Publicado: (2016)

Eribulin targets a ch-TOG-dependent directed migration of cancer cells
por: Chanez, Brice, et al.
Publicado: (2015)

Eribulin Mesylate Targets Human Telomerase Reverse Transcriptase in Ovarian Cancer Cells
por: Yamaguchi, Satoko, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_5uf6inc5kvsml9t6pgcof774vn